REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS

REGENXBIO (NASDAQ:RGNX) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.35, FiscalAI reports. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The firm had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million.

Here are the key takeaways from REGENXBIO’s conference call:

• REGENXBIO ended the quarter with more than $310 million pro forma, following a $100 million AbbVie milestone and a $108 million follow-on offering. Management expects this to fund operations into Q4 2027, including the anticipated RGX-202 PDUFA date.
• RGX-202 enrollment and dosing in the confirmatory Duchenne muscular dystrophy study were completed ahead of schedule, with more than 60 patients across pivotal and confirmatory studies. The company plans to submit the first BLA module in Q3 2026 and initiate the global AFFINITY RISE trial in the first half of 2027.
• The FDA agreed that RGX-121’s existing data are sufficient for accelerated-approval review and said no additional studies, including a randomized controlled trial, are required for BLA resubmission. REGENXBIO plans to resubmit the application in Q3 2026 with longer-term efficacy, safety, imaging, and neurocognitive data.
• REGENXBIO and AbbVie began the Phase IIb/III NAAVIGATE study of sura-vec in diabetic retinopathy, triggering the $100 million milestone payment. The partners expect fourth-quarter top-line results from the ATMOSPHERE and ASCENT wet AMD studies, while longer-term follow-up showed durable effects and favorable safety through five years in wet AMD and 2.5 years in diabetic retinopathy.
• The company acknowledged that its U.S. patent covering Zolgensma has expired, although royalties will continue in roughly 20 countries outside the United States. Management highlighted Evrysdi coverage and potential future royalties from Itvisma as offsets, but did not provide specific royalty-rate guidance.

REGENXBIO Stock Performance

NASDAQ:RGNX traded up $0.78 during mid-day trading on Thursday, hitting $11.28. The company had a trading volume of 1,766,472 shares, compared to its average volume of 1,848,277. REGENXBIO has a fifty-two week low of $5.45 and a fifty-two week high of $16.19. The business’s fifty day moving average is $9.94 and its two-hundred day moving average is $9.42. The firm has a market cap of $583.18 million, a P/E ratio of -2.01 and a beta of 0.94.

Insider Buying and Selling

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $13.64, for a total value of $29,476.04. Following the completion of the sale, the insider owned 213,009 shares of the company’s stock, valued at approximately $2,905,442.76. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 73,803 shares of company stock valued at $886,937 over the last ninety days. 14.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG raised its holdings in REGENXBIO by 0.8% during the fourth quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after acquiring an additional 1,527 shares in the last quarter. Captrust Financial Advisors grew its stake in REGENXBIO by 13.2% in the fourth quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 1,781 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of REGENXBIO by 12.2% during the 4th quarter. Intech Investment Management LLC now owns 21,367 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 2,327 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its holdings in shares of REGENXBIO by 24.0% in the 4th quarter. Focus Partners Advisor Solutions LLC now owns 12,676 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 2,455 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of REGENXBIO by 18.8% in the third quarter. BNP Paribas Financial Markets now owns 17,724 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 2,800 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

RGNX has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and set a $26.00 price objective on shares of REGENXBIO in a report on Wednesday, July 1st. Barclays reduced their target price on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Zacks Research downgraded shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Morgan Stanley set a $16.00 price target on shares of REGENXBIO in a report on Friday, May 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.82.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.